Mizuho's Price Target Increase#
Mizuho has raised its price target for Elevance Health shares (NYSE:ELV) from $350 to $385. This adjustment comes after the company reported strong first-quarter results for 2026 and maintains an Outperform rating on the stock.
Strong Q1 Performance#
Elevance Health's recent earnings report showed adjusted earnings per share of $12.58, exceeding analysts' expectations by 14%. The company also reported a medical loss ratio of 86.80%, which is slightly better than the anticipated 87.05%. A medical loss ratio measures the percentage of premium revenue spent on medical care, and a lower ratio indicates better efficiency in managing healthcare costs.
Positive Trends and Outlook#
Mizuho noted that healthcare utilization trends are currently high but may be reaching their peak, similar to trends seen in other managed care companies. They believe that the current pricing cycle could lead to improved profit margins over time. The firm views Elevance's earnings guidance for 2026 as not only achievable but potentially surpassable if current trends continue.
Analyst Consensus#
Following Elevance's strong performance, several other analysts have also raised their price targets. Bernstein increased its target to $424, Guggenheim to $399, and Barclays to $408, all citing various positive factors such as Medicaid performance and favorable claims development. These adjustments reflect a generally optimistic outlook for Elevance Health's financial health and strategic direction.